Figure 1.

TFT selectively inhibits the proliferation of TNBC cells in vitro. (A) MDA-MB-231 cells were treated in triplicate with, or without, (control), vehicle DMSO, each indicated drug for 48 hours and the cell viability was assayed. (B) MCF-10A, MCF-7, MDA-MB-231, BT-549 and Hs578T cells were treated in triplicate with vehicle (control) or the indicated doses of TFT and their cell viability was measured by MTT or counted (C). (D) Flow cytometry analysis of proliferative cells after labeled with CFSE. (E) TFT inhibits the clonogenicity of TNBC cells. (F) Immunoblot analysis of cell proliferative regulators. Data are representative images, flow cytometry histograms or expressed as the mean ± SEM of each group of cells from three separate experiments. *P<0.05, **P<0.01, ***P<0.001 vs. the control.